Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a relatively newer emerging group of oral hypoglycemic agents in use for the treatment of T2DM [2] as selective and reversible inhibitors of the SGLT2 co-transporter [3]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.